Comparison of efficacy of liraglutide, metformin and gliclazide MR on hepatic lipid content in patients with type 2 diabetes (T2DM) and non-alcoholic fatty liver (NAFLD)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004660

Enrollment

Unknown

Registered

2014-09-21

Start date

2014-06-03

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes, Non-alcoholic fatty liver

Interventions

A:Liraglutide

B:Metformin

C:Metformin

Eligibility

Sex/Gender

Male

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18-70 years;2. Type 2 diabetes mellitus;3. Not used antidiabetic drugs within 3 months;4. HbA1c(7-10%);5. Presence of fatty liver disease (hepatic fat content = 20% by quantitative ultrasonography);6. Female subjects:post-menopausal women, take contraceptive measures three months before the test screening and can persist throughout the experimental period;7. Body mass index (BMI) 20-35kg/m2, and stable Weight 3 months(less than 10% volatility);8. patients signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Used antidiabetic drugs or any other possible hepatic steatosis associated with drugs within the past three months; 2. Suffering from pancreatitis or other pancreatic diseases or have other similar history; 3. GLP-1 analogs or sulfonylurea allergy history; 4. Liver dysfunction (aspartate aminotransferase = 2.5 times of the normalupper limit); 5. Moderate to severe renal insufficiency (eGFR 14 units / week; male subjects drinking> 21 units/week; 7. A history of metabolic or autoimmune liver diseases or viral hepatitis diseases; 8. A history of medullary thyroid carcinoma, multiple endocrine neoplasia 2 or family history; 9. Congestive heart failure (NYHA grade ? - ? grade); 10. Severe gastrointestinal diseases; 11. Other serious concomitant diseases; 12. Pregnant or planning pregnancy; 13. The researchers believe that the subjects with proliferative retinopathy or macular degeneration need urgentl treatment; 14. Subjects are using unknown ingredients or non herbal medicine preparations or local medicine, researchers believe that during the test the dose of traditional Chinese medicines can not be adjusted or disabled.

Design outcomes

Primary

Measure	Time frame
Liver fat content(Quantitative ultrasound);HbA1;	—

Secondary

Measure	Time frame
Liver function;blood inflammatory markers;Lipid levels;Body mass index;WH;	—

Countries

china

Contacts

Public ContactDalong Zhu

zhudldr@gmail.com+86 13805150781

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026